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Abstract
Glucagon-like peptide 1 receptor agonists (GLP-1RAs), which are currently used for the 
treatment of type 2 diabetes, have recently been proposed as anti-obesity drugs, due 
to their relevant effects on weight loss. Furthermore, dual agonists for both GLP-1R 
and glucagon receptor (GCGR) are under investigation for their promising action 
on adiposity, although underlying mechanisms still need to be clarified. We have 
recently demonstrated that GLP-1 and liraglutide interfere with the proliferation and 
differentiation of human adipose precursors, supporting the hypothesis of a peripheral 
action of GLP-1RA on weight. Here, we investigated glucagon activity in an in vitro 
model of primary human adipose-derived stem cells (ASCs). Glucagon significantly 
inhibited ASC proliferation in a dose- and time-dependent manner, as evaluated by cell 
count and thymidine incorporation. When added during in vitro-induced adipogenesis, 
glucagon significantly reduced adipocyte differentiation, as demonstrated by the 
evaluation of intracellular fat content and quantitative expression of early and mature 
adipocyte markers (PPARγ and FABP4, HSL). Notably, the inhibitory effect of glucagon 
on cell proliferation and adipogenesis was reversed by specific GLP-1R (exendin-9) and 
GCGR (des-His1-Glu9-glucagon(1–29)) antagonists. The presence of both receptors was 
demonstrated by Western blot, immunofluorescence and cytofluorimetric analysis 
of ASCs. In conclusion, we demonstrated a direct inhibitory action of glucagon on the 
proliferation and differentiation of human adipose precursors, which seems to involve 
both GLP-1R and GCGR. These findings suggest that the adipose stem compartment is 
a novel target of glucagon, possibly contributing to the weight loss obtained in vivo with 
dual GLP-1R/glucagon agonists.
Introduction
Obesity is one of the most critical risk factor for the 
development of type 2 diabetes (T2D); in fact, about 
90% of persons with diabetes is obese or overweight 
(Pappachan et al. 2017). This led to the use of the term 
‘diabesity’, indicating such a strong association between 
the two pathologies (Astrup & Finer 2000).
Among glucose-lowering drugs used for the treatment 
of T2D, glucagon-like peptide-1 (GLP-1) receptor agonists 
(GLP-1RAs) reduce body weight and adiposity both in 
T2D and in non-diabetic obese subjects (Monami et  al. 
2012, Pi-Sunyer et al. 2015, Cantini et al. 2016). One of 
the GLP-1RAs, liraglutide, has recently been approved for 
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the treatment of obesity. In addition, a 4-week-treatment 
of healthy and obese subjects with oxyntomodulin, 
an endogenous enteroendocrine peptide that acts 
as a dual agonist for GLP-1R and glucagon receptor 
(GCGR), reduced food intake and enhanced energy 
expenditure, thus resulting in a significant body weight 
loss (Wynne et al. 2005, Bagger et al. 2015). Consistently, 
pharmacological dual agonists acting on GLP-1R/GCGR 
have shown a greater efficacy in inducing weight loss 
in diet-induced obese mice in comparison with specific 
GLP-1R agonists (Pocai et  al. 2009). Encouraging results 
have also been obtained in humans with the use of GLP-1/
glucagon dual agonists combining the lipolytic activity of 
glucagon with the glucose-dependent insulinotropic and 
weight loss action of GLP-1, without inducing glucagon-
associated hyperglycemia (Sánchez-Garrido et  al. 2017). 
Compared to placebo, the dual agonist AR425899 
significantly reduced fasting plasma glucose and glycated 
haemoglobin, together with body weight, in patients with 
T2D (Tillner et al. 2019). However, presently available data 
are still insufficient to establish whether dual GLP-1R/
GCGR agonists are more effective than the single GLP-1 
agonists in the treatment of obesity and diabetes.
In an in vitro cell model of human adipose precursors 
(ASCs) derived from abdominal fat depots and 
characterized by our group (Baglioni et al. 2009, 2012), 
liraglutide and GLP-1 have recently been demonstrated to 
interfere with adipocyte proliferation and differentiation 
(Cantini et  al. 2015, 2017), as further confirmed by El 
Bekay and colleagues (El Bekay et al. 2016). These effects 
seem to be mediated by the classical GLP-1 receptor, as 
they are reverted by the GLP-1R antagonist exendin 9-39 
(Cantini et al. 2015, 2017). However, similar effects have 
also been obtained with the DPP4-cleaved form GLP-1 
(9-36), which displays a reduced binding for the classical 
GLP-1R; the effects of GLP-1 (9-36) are not reversible 
by exendin 9-39 (Cantini et  al. 2017). All together, 
these findings suggest the involvement of alternative 
mechanisms in mediating GLP-1 effects in ASCs (Cantini 
et al. 2016).
Glucagon, a 29 amino acid peptide produced by the 
enzymatic cleavage exerted by the prohormone-convertase 
2 on the same proglucagon precursor generating GLP-1 
and oxyntomodulin, is secreted from the pancreatic 
alpha cells under hypoglycaemic conditions to restore 
blood glucose levels (Habegger et al. 2010). Its secretion 
is finely regulated by intestinal peptides, such as GLP-1, 
oxyntomodulin and glucose-dependent insulinotropic 
peptide (GIP), but also by glucagon itself in a paracrine 
way (Wewer et  al. 2016, Müller et  al. 2017). Glucagon 
reduces food intake in rodents and humans; moreover, a 
sustained activation of GCGR has been demonstrated to 
enhance lipolysis (Day et al. 2009), although underlying 
mechanisms are still unclear.
The present study assessed the direct effects of 
glucagon on the stem cell compartment of human adipose 
tissue, characterizing the receptors involved.
Materials and methods
Materials
Media and sera for cell cultures were purchased from 
Sigma-Aldrich and tissue plastic ware was obtained from 
Corning (Milan, Italy). AdipoRed was from Lonza (Milan, 
Italy). Glucagon, exendin (9-39), [des-His1-Glu9-glucagon 
(1–29)] and GLP-1(7-36) were purchased from Sigma-
Aldrich, as well as the other reagents for cell cultures, 
fluorescence microscopy, except where differently 
indicated.
Human adipose-derived stem (ASC) cell populations
Abdominal adipose stem cell populations (ASCs) 
previously isolated and characterized (Baglioni et al. 2009, 
2012) from nine morbidly obese subjects (two males and 
seven females: mean age ± s.d.: 54 ± 13 years; BMI ± s.d.: 
39.2 ± 7.7 kg/m2), who underwent bariatric surgery at 
Careggi University Hospital (following written informed 
consent, Local Ethical Committee’s approval Ref. Protocol 
58-11), have been used in this study. ASCs were cultured 
in DMEM containing 20% fetal bovine serum (FBS), 
100 mg/mL streptomycin, 100 U/mL penicillin, 2 mM 
l-glutamine, and 1 µg/mL amphotericin-B, at 37°C in 
humidified atmosphere with 5% CO2, and used between 
passages 2 and 6. Each experiment was performed at 
least three times using ASCs derived from at least three 
independent subjects. In all experiments, glucagon, 
GLP-1 and receptors’ antagonists have been added from 
the beginning and freshly re-added every 3 days.
ASC viability and proliferation assay
Cell count
Seeded cells (7 × 103) were treated with glucagon (1-10-
100 nM) for the indicated times, and then trypsinized 
and counted in the haemocytometer. Mean cell number 
was obtained by counting at least four replicates for each 
point in each experiment. Dead cells were excluded by 
trypan blue test.
AUTHOR COPY ONLY
https://doi.org/10.1530/JME-19-0095
https://jme.bioscientifica.com © 2019 Society for Endocrinology
Printed in Great Britain
Published by Bioscientifica Ltd.
25163 4:G Cantini et al. Glucagon effect in adipose  
stem cells
Journal of Molecular 
Endocrinology
DNA synthesis assay – [3H]thymidine uptake
DNA synthesis was evaluated according to the amount 
of [3H]thymidine (Perkin Elmer) incorporated into 
trichloroacetic acid (TCA)-precipitated materials. Cells 
grown until 70% confluence and 24 h-starved, were 
treated with glucagon (10 and 100 nM) for 24 and 48 h, 
pulsing them with 0.5 μCi/mL [3H]TdR (6.7 Ci/mmol) 
for 4 h before stopping proliferation in 10% ice-cold 
TCA. After washing in 5% TCA, cells were solubilized in 
0.25 N NaOH, at 37°C and radioactivity was measured 
on a scintillation beta-counter (Tri-Carb 2800TR Liquid 
Scintillation Analyzer, Perkin Elmer). Experiments 
were performed in quadruplicate in three independent 
cell populations.
Cytofluorimetric cell count
Seven thousand ASCs seeded in 12-well plates and 
grown at confluence were treated with glucagon (1-10-
100 nM). At different time points (24, 48, 72 h) cells were 
trypsinized and analysed with a Muse™ automated cell 
analyser (Merck Millipore) using Muse™ Count & Viability 
(cat#MCH100102, Merck Millipore) assay, according to 
the manufacturer’s instructions.
Cytofluorimetric apoptotic evaluation
After 24, 48 and 72-h treatment with glucagon (10 and 
100 nM), ASCs were trypsinized and analysed with a 
Muse™ automated cell analyser (Merck Millipore) for the 
early apoptosis detection using Muse™ Annexin V/Dead 
Cell (cat#MCH100105, Merck Millipore) assay, according 
to the manufacturer’s instructions.
Cytofluorimetric cell cycle analysis
ASCs treated for 24 and 48 h with glucagon (10 and 100 nM) 
were trypsinized and analysed with a Muse™ automated 
cell analyser (Merck Millipore) for the evaluation of cell 
cycle using Muse™ Cell Cycle kit (cat#MCH100106, 
Merck Millipore) assay, according to the manufacturer’s 
instructions.
In vitro-adipose differentiation
ASCs (105 cells) were cultured in a 6-well plate in 10% 
FBS-DMEM, 0.5 mM 3-isobutyl-1-methylxanthine, 1 µM 
dexamethasone, 200 µM indomethacin and 10 µM 
insulin for 2 weeks, and then shifted to 10% FBS-DMEM 
containing 1.7 µM insulin for another week (Baglioni et al. 
2009, 2012). Glucagon and receptors’ antagonists have 
been added from the beginning of adipose differentiation. 
Stimuli have been freshly re-added every 3 days.
Intracellular triglyceride staining techniques
Oil Red O – AdipoRed
Adipose differentiation was assessed by Oil Red O or 
AdipoRed staining of intracellular neutral lipids in 
in-vitro-differentiated adipocytes, observed under optical 
or fluorescence microscopy, respectively.
AdipoRed staining of intracellular lipid droplets
ASCs grown on plastics or on glass coverslips were 
subjected to adipose differentiation in the absence or 
presence of glucagon (1-10-100 nM), and then were treated 
with the AdipoRed staining as described earlier (Cantini 
et  al. 2015). Quantitative spectrofluorimetric detection 
of AdipoRed fluorescence emission was measured with 
an ELISA plate reader (Wallac 1420, Perkin Elmer) at 
485/572 nm excitation/emission. Specific absorbance of 
the intracellular lipid droplets in differentiated adipocytes 
was calculated as fold increase on unspecific absorbance 
of undifferentiated ASCs used as control, after the blank 
subtraction. This value correlates with the entity of 
differentiation (number and size of mature adipocytes 
formed). Each point has been obtained in ten replicates 
from five independent experiments.
The AdipoRed assay is referred to the total intracellular 
accumulation of triglycerides in all differentiated 
adipocytes and is not considered a measurement of the 
single cell intracellular lipid content.
After fixation in 4% paraformaldehyde, cells were 
counterstained with DAPI ((1:2000), Sigma-Aldrich) and 
the coverslips mounted using the ProLong® Gold Antifade 
Mountant (ThermoFisher Scientific). Fluorescence images 
were acquired with a Leica DM4000 epifluorescence 
microscope (Leica Microsystems GmbH).
mRNA isolation and quantitative real-time RT-PCR
mRNA isolation from cells was performed as previously 
detailed (Baglioni et al. 2009, 2012) and quantitative real-
time RT-PCR (qRT-PCR) was carried out using primers and 
probes for FABP4, HSL, PPARγ and GAPDH genes (Taqman 
Gene Expression Assay, Life Technologies, respective codes: 
HS00609791_m1, Hs00193510_m1, Hs00234592_m1, 
FAM-MGB 4325934-1301038). The amount of target, 
normalized to the endogenous reference gene (GAPDH) 
and relative to a calibrator (Stratagene, La Jolla, CA, USA) 
was calculated by 2−∆∆Ct.
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SDS-PAGE and Western Blot analysis
ASC proteins were extracted in RIPA buffer (20 mM Tris, pH 
7.4, 150 mM NaCl, 0.5% Triton-100, 1 mM Na3VO4, 1 mM 
PMSF). Thirty micrograms of proteins were separated by 
reducing SDS-PAGE stain-free precast gels® (Bio-Rad) and 
transferred to PVDF membranes (Trans-Blot® TurboTM, 
Bio-Rad).
Membranes were probes with the following primary 
antibodies: polyclonal anti-GLP-1R (1:200, sc-34637; 
Santa Cruz Biotechnology), monoclonal anti-GLP-1R 
(1:1000, sc-390773; Santa Cruz Biotechnology), polyclonal 
anti-GLP-1R (1:500, ab186051; Abcam), anti-glucagon 
receptor (1:200, sc34641; Santa Cruz Biotechnology). Each 
membrane was incubated overnight at 4°C with primary 
antibodies followed by peroxidase-conjugated secondary 
IgGs (1:2000). Image acquisition and analysis were 
performed with Image Lab software on a ChemiDoc TM 
Touch instrument (Bio-Rad), using fluorescence emission 
of protein bands separated on stain-free gels for the total 
lane normalization. All Western blot experiments were 
repeated at least three times.
GLP-1R/GCGR detection in ASCs by flow 
cytometry analysis
Analysis of GLP-1R/GCGR expression in ASC populations 
was performed by using the FITC-conjugated monoclonal/
polyclonal antibodies and their respective negative 
controls (secondary antibodies, Sigma-Aldrich). Cells were 
acquired from each sample on FACScan flow cytometer 
(Becton–Dickinson) and green fluorescence was detected 
by the FL1 (515–555 nm wavelength band) detectors. Flow 
cytometric analysis was stopped when 1000 events were 
acquired.
Fluorescence Immunocytochemistry
Ten thousand cells grown on glass coverslips in a six-well 
plate were fixed with 4% paraformaldehyde, for 10 min, 
at room temperature. PBS-washed coverslips were blocked 
in 5% goat serum, and then incubated for 2 h at room 
temperature with the monoclonal anti-GLP1R (1:50, 
sc-390773), polyclonal anti-GLP-1R (1:50, ab186051), 
or anti-glucagon receptor (1:20, sc34641) diluted in 5% 
goat serum. Coverslips were incubated with an FITC-
conjugated anti-goat or anti-mouse IgG antibody (1:100, 
Sigma-Aldrich) for 1 h, and then were mounted using the 
ProLong® Gold Antifade Mountant with DAPI (#P36962, 
ThermoFisher Scientific).
Images were acquired with a Leica DM4000 
epifluorescence microscope (Leica Microsystems GmbH). 
Negative controls (not shown) were performed avoiding 
primary antibodies.
Statistical analysis
Statistical analysis was performed using SPSS 25.0 software 
(SPSS Inc.). The Kolmogorov–Smirnov test was used to verify 
the normal distribution of data, which was expressed as 
mean ± s.e. One-way ANOVA followed by post hoc Dunnett’s 
test was applied for multiple comparisons, while Student’s t 
test was applied for analysis of two classes of data. A P < 0.05 
value was considered statistically significant.
Results
Glucagon exerts an anti-proliferative effect on 
human adipose precursor cells
The in vitro administration of increasing concentrations 
of glucagon (1-10-100 nM) resulted in a reduction in the 
number of human ASCs. ASC exponential growth was 
significantly inhibited by glucagon, in a dose- and time-
dependent manner, with the maximal effect for the highest 
dose (37%), as evaluated by direct cell count, observed in the 
third day (Fig. 1A). The decrease in cell number following 
glucagon treatment was confirmed by FACScan analysis, 
which highlighted a significant increase in the number of 
dead cells, starting from day 1 with glucagon 100 nM; this 
reduction was statistically significant for the lower (10 nM) 
dose at days 2 and 3 (Fig. 1B and C). A significant reduction 
in the proliferation rate in response to glucagon (10-100 nM) 
was demonstrated through thymidine incorporation assay 
(Fig. 1D). This finding was confirmed by a significant 
reduction in the number of cells in the S-phase of the cell cycle 
(analysed by FACScan) following 24-h glucagon exposure 
(14 and 19% for 10-100 nM glucagon) and 48-h glucagon 
(25% for both doses) (Fig. 1E and F). No significant effect of 
glucagon on cell apoptosis, as evaluated by cytofluorimetric 
evaluation of annexin V exposure, was observed at any time 
points (Fig. 2A and B).
Glucagon inhibits in vitro-induced adipogenesis
To assess glucagon effects on the adipogenic potential 
of adipose precursors, cultured ASCs were in vitro-
differentiated in the presence of increasing concentrations 
of glucagon (1-10-100 nM). AdipoRed and Oil Red O 
staining of intracellular triglyceride depots, observed under 
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fluorescence (Fig. 3A, B, C, D, E, F, G and H) or optical 
(Fig. 3I, J, K and L) microscope, revealed a lower number 
of differentiated adipocytes with smaller lipid droplets 
in glucagon-treated wells. The quantitative evaluation 
of AdipoRed assay confirmed a statistically significant 
reduction in fluorescence intensity in ASCs differentiated 
with increasing doses of glucagon (fold decrease vs ADIPO: 
1.1, 1.5, 1.4 for glucagon 1-10-100 nM, respectively) Fig. 3M.
In order to confirm the inhibitory effect of glucagon 
on adipogenesis, gene expression of the specific adipose 
differentiation markers, the early master gene PPARγ and 
the fatty acid-binding protein-4 (FABP4) and hormone-
sensitive lipase (HSL), as marker of mature adipocytes, 
were quantified by qRT-PCR TaqMan analysis. A 
significant decrease in the expression level of analysed 
genes in in vitro-differentiated adipocytes was detected in 
the presence of glucagon (% inhibition vs ADIPO: 33, 35, 
29%, for PPARγ, 28, 66, 37% for FABP4 and 46, 54, 37% 
for HSL, for glucagon 1-10-100 nM, respectively) (Fig. 3N).
ASCs express GLP-1R and GCGR
In our previous studies, we observed that the anti-
proliferative and anti-lipogenic effect exerted by 
liraglutide on ASCs seems to be at least partially mediated 
by the classical GLP-1R (Cantini et al. 2015). However, the 
Figure 1
The anti-proliferative action of glucagon in adipose precursors. ASCs were untreated (CTRL) or treated for 1, 2 or 3 days with increasing concentration 
(1-10-100 nM) of glucagon. (A) Haemocytometer cell-counting results are expressed as mean ± s.e. (B) Representative scatter plots of cytofluorimetric 
evaluation of cell viability are shown; (C) bar-graphs represent mean ± s.e. of cell percentages. (D) Data represent mean ± s.e. cpm after a 4-h pulse of 
[3H]-thymidine in ASCs untreated/treated for 24–48 h with 10-100 nM glucagon. (E) Representative scatter plots of DNA content index are presented; (F) 
data obtained from cell cycle analysis are indicated as mean ± s.e. of cell percentage in ASCs untreated/treated for 24–48 h with 10-100 nM glucagon. 
Statistical analysis was performed with ANOVA (F and P value are indicated) followed by Dunnett’s post hoc test: *P < 0.05, **P < 0.01, §P < 0.000 vs 
respective Ctrl, n = 5 independent experiments.
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expression of GLP-1R in the adipose tissue and in adipose 
precursors is still debated (Vendrell et al. 2011, Muscogiuri 
et  al. 2014, Cantini et  al. 2016, El Bekay et  al. 2016). 
Therefore, we evaluated the expression of GLP-1R and 
GCGR in ASCs using different complementary techniques 
and different monoclonal and polyclonal antibodies. 
First, we confirmed GCGR and GLP-1R protein expression 
on the cell surface by immunofluorescence cytochemistry 
(Fig. 4A). The receptor positivity detected by fluorescence 
microscopy was confirmed by FACScan evaluation of ASCs 
using the same antibodies against GCGR and GLP-1R 
(Fig. 4B). Finally, the presence of both receptors was 
detected both in ASCs and in the corresponding adipose 
tissue (AT) samples by Western blot analysis at the 
expected molecular weight (Fig. 4C).
An interplay between GCGR and GLP-1R is involved 
in mediating glucagon effects
We had previously reported that the effects of GLP-
1RAs such as liraglutide and native GLP-1(7-37) on 
human adipose precursors are significantly attenuated 
Figure 2
Glucagon stimulation does not affect apoptosis in 
adipose precursors. ASCs were untreated (CTRL) 
or treated for 1, 2 or 3 days with increasing 
concentration (10-100 nM) of glucagon. (A) 
Representative scatter plots of cytofluorimetric 
evaluation of annexin V are shown. (B) Bar graphs 
represent mean ± s.e. of cell percentages. 
Statistical analysis was performed with ANOVA 
resulting in no statistically significant differences, 
n = 3 independent experiments. A full colour 
version of this figure is available at https://doi.
org/10.1530/JME-19-0095.
Figure 3
Glucagon interferes with the in vitro-induced adipose differentiation. ASCs were untreated (ASC) or in vitro induced to differentiate towards the adipose 
phenotype with the specific inductive media (ADIPO) alone or in the presence of increasing concentration (1-10-100 nM) of glucagon. Representative 
images of in vitro-derived adipocytes stained with AdipoRed fluorescence reagent (A–H) or Oil Red O staining (I–L), captured by epifluorescence or optical 
microscopy, respectively. Any Oil Red O or AdipoRed staining was present in undifferentiated ASC controls (not shown). Magnification (20× A–D, 40× E–L). 
(M) Quantitative evaluation of intracellular triglyceride depots expressed as mean ± s.e. absorbance fold increase (FI) vs ASC after spectrofluorometric 
measurement of AdipoRed staining. Percentages of glucagon inhibitory effect in lipid content are indicated. Statistical analysis was performed with 
ANOVA (F = 5.915; P = 0.001) followed by Dunnett’s post hoc test: §P < 0.000 vs undifferentiated ASCs, *P < 0.005, **P < 0.000 vs ADIPO, n = 5 independent 
experiments. (N) TaqMan qRT-PCR evaluation of adipose marker gene expression in in-vitro-differentiated adipocytes alone or treated with increasing 
concentration (1-10-100nM) of glucagon: bar-graph represents mean ± s.e. gene expression fold increase (FI) vs ADIPO. Statistical analysis was performed 
with ANOVA followed by Dunnett’s post hoc test: *P < 0.05, **P < 0.001 vs ADIPO, n = 5 independent experiments.
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or completely reverted in the presence of the specific 
GLP-1R antagonist exendin 9-39 (Cantini et  al. 2015, 
2017). An inhibitory effect similar to that observed with 
liraglutide had been observed with the cleaved GLP-1 
form, GLP-1(9-36), which displays a reduced binding 
ability to the classical receptor. In order to better clarify 
the role of GLP-1R and GCGR in mediating the similar 
effects observed with GLP-1RAs and glucagon in ASCs, we 
used the specific glucagon receptor antagonist, des-His1-
[Glu9]-glucagon(1–29) (GI) (Unson et al. 1987, Post et al. 
1993, Chepurny et al. 2019), along with the antagonist of 
GLP-1R exendin 9-39 (EX). When cell count experiments 
were repeated in the presence of glucagon alone or 
in combination with GI (10 nM) or EX (10 nM), the 
inhibitory effect exerted by glucagon on ASC proliferation 
was significantly reverted not only by GI (86, 103, 97% for 
24, 48, 72-h treatment, respectively), but also by EX (88, 
96, 91% for 24, 48, 72-h treatment, respectively), Fig. 5A. 
Similarly, the inhibitory effect exerted by GLP-1 on ASC 
proliferation was significantly dampened and reversed in 
the presence of GI (92, 104, 92% for 24, 48, 72-h treatment, 
respectively), Fig. 5B. The engagement of both receptors 
in mediating the effect of glucagon on cell proliferation 
was further supported by the absence of any synergistic 
effect between glucagon and GLP-1 when added to the 
cells at the equimolar dose of 10 nM (Fig. 5C).
When the two antagonists of GLP-1R and GCGR 
were added with glucagon during in vitro-induced adipose 
differentiation (GI and exendin 9-39, 10 nM), a significant 
reversion of glucagon inhibition of adipogenesis was 
observed with both antagonists, as shown by AdipoRed 
intracellular lipid quantitative staining (reversion 
percentage of 79 and 93% for GI and EX, respectively), 
Fig. 6A. These findings were further confirmed by the 
reversion of glucagon inhibition of FABP4 and HSL gene 
expression observed in the presence of each antagonist 
(GI: 88 and 77% for FABP4 and HSL, respectively; exendin 
9–39: 104 and 95% for FABP4 and HSL, respectively) (Fig. 
6B). The simultaneous addition of the two receptor’s 
antagonists together with glucagon showed a statistically 
significant reversion of the adipogenesis inhibition higher 
than those observed with single antagonist stimulation 
(149 and 133% vs GI or EX alone), as assessed by 
quantitative evaluation of FABP4 gene expression (Fig. 
6C). The percentage of FABP4 expression versus ADIPO 
was 95, 110, 126% for GI, EX and GI + EX, respectively 
(Fig. 6C). Taken together these findings suggested that the 
combination of inhibitors totally recovered the inhibitory 
effect of glucagon even to a higher extent than the single 
antagonist.
Discussion
Although prior pharmacological approaches to obesity had 
failed to achieve and maintain in the long-term a relevant 
weight loss, some GLP-1R agonists used for the treatment 
of T2D have been recently developed as anti-obesity 
drugs. In order to improve the effects on weight of GLP-1 
Figure 4
GCGR and GLP-1R expression in human adipose 
precursor cells. (A) ASCs were subjected to an 
immunocytochemistry using the different 
antibodies for GCGR and GLP-1R, as specified in 
the methods section. Representative images of 
cells incubated with GCGR primary antibody 
(panels b and c), monoclonal (panels e-f) and 
polyclonal (panels h-i) primary GLP-1R antibodies 
and visualized on epifluorescence microscopy are 
shown. Negative controls (panels a-d-g) avoiding 
the primary antibody are shown. Nuclear 
counterstaining with DAPI is presented (blue 
signal). Magnification is 20×. (B) Cytofluorimetric 
evaluation of GCGR and GLP-1R on cell surface. 
Representative scatter plots are shown: data is 
expressed as the mean ± s.d. of positive cells in 
n = 3 independent experiments. (C) Western blot 
analysis of GCGR and GLP-1R expression in 
different ASC populations compared to the 
positive controls (AT, adipose tissue and HT,  
heart samples). Protein ladder bands are shown 
in the left.
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(Tan et al. 2013, Tillner et al. 2019), the use of glucagon in 
association with GLP-1 (Day et al. 2009) or of dual agonists 
for both GLP-1 and glucagon receptors (Pocai et al. 2009, 
Tillner et  al. 2019) seems to be a promising approach. 
Specific research in this field has raised a novel interest 
in the systemic catabolic properties of glucagon, besides 
its well-known role in regulating glucose homeostasis as 
counter-actor of insulin. In in vivo mouse models of obesity, 
treatment with dual agonist determined enhanced weight 
loss and a greater improvement in several metabolic 
parameters in comparison with selective GLP-1 agonists 
(Pocai et al. 2009). Indeed, glucagon-induced suppression 
of appetite and increase of energy expenditure were 
described a long time ago, together with the stimulation 
of catabolic processes alternative to glucose consumption, 
such as amino acid and lipid catabolism, to maintain the 
fuel for the organism and carbonic skeletons to support 
gluconeogenesis (Ahrén 2015).
We show here novel direct effects of glucagon on 
the stem compartment of human AT, in addition to 
the stimulation of lipolysis already known for mature 
adipocytes (Bertin et al. 2001, Arafat et al. 2013). Glucagon 
administration to human primary ASC significantly 
inhibits cell proliferation, reducing cell precursor number 
and in vitro-induced adipogenesis; this is demonstrated 
not only by a decrease in intracellular lipid droplet 
accumulation but also in a lower expression of mature 
adipocyte markers, such as HSL and FABP4 and the early 
master gene, such as PPARγ. These effects may contribute 
to the weight loss observed in treated subjects through a 
direct action on the AT. Notably, our results suggest that 
glucagon could act not only exerting a direct action on the 
mature adipocytes, but also affecting the expansion of the 
adipose compartment, by interfering more precociously 
on the number of precursors undergoing adipogenesis 
(limiting their proliferation and reducing the number 
of mature adipocytes formed), and thus resulting in a 
longer lasting effect. The inhibition of recruitment and 
differentiation of precursors into adipocytes might lead 
to hypertrophy and dysfunction in adipose cells or to 
ectopic accumulation of lipids in other depots, leading 
to the development of insulin resistance. This specific 
issue, which would require in vivo animal studies, was not 
within the aim of the present study. However, available 
data on dual agonists for GLP-1 and glucagon receptors 
have so far excluded any detrimental effect on insulin 
resistance; conversely, they showed a beneficial effect on 
blood glucose beside weight loss (Pocai et  al. 2009, Tan 
et al. 2013, Sánchez-Garrido et al. 2017, Tillner et al. 2019).
We had recently demonstrated that liraglutide 
(Cantini et  al. 2015), and to a lesser extent native 
GLP-1 (Cantini et  al. 2017), exert similar effects in the 
same adipose precursor cell model at the equimolar 
concentration of 10 nM. Both liraglutide (Cantini et  al. 
2015) and glucagon (as we show in the present paper) 
reduce ASC number by inhibiting cell proliferation and 
Figure 5
GCGR and GLP-1R involvement underlying the anti-proliferative effect of 
glucagon in human adipose precursor cells. (A) ASCs were untreated 
(CTRL) or treated for 1, 2 or 3 days with 10 nM glucagon alone or 
combined with an equimolar concentration (10 nM) of the GCGR 
antagonist, des-His1-Glu9-glucagon(1–29) (GI) or the GLP-1R antagonist 
exendin 9-39, (EX): results are expressed as mean ± s.e. of direct cell count. 
(B) ASCs were untreated (CTRL) or treated for 1, 2 or 3 days with 10 nM 
GLP-1 alone or combined with an equimolar concentration (10 nM) of the 
GCGR antagonist, des-His1-Glu9-glucagon(1–29) (GI): quantitative results 
are expressed as mean ± s.e. of direct cell count. (C) ASCs were untreated 
(CTRL) or treated for 1, 2 or 3 days with 10 nM glucagon (GLUC) alone or 
combined with an equimolar concentration (10 nM) of GLP-1: results are 
expressed as mean ± s.e. of direct cell count. Statistical analysis was 
performed with Student’s t test: *P < 0.05, **P < 0.01, n = 3 independent 
experiments.
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inducing cell death. However, liraglutide only was able 
to stimulate cell apoptosis, whereas glucagon seemed to 
induce cell death in a non-apoptotic manner. In particular, 
the significant reduction in the proliferation rate (of about 
40%) measured by thymidine incorporation at the two 
highest doses of glucagon (10-100 nM) seems to be due to 
a reduction in the number of cells entering the S-phase.
Despite the opposite contribution of glucagon and 
GLP-1 in the control of glucose homeostasis, a convergence 
of action of the two molecules is not surprising, as they share 
large sequences of homology and derive from alternative 
post-translational splicing from the same encoding gene. 
A further suggestive clue supporting the analogy in the 
activities of the two molecules is represented by their 
respective receptors, GCGR for glucagon and GLP-1R for 
GLP-1. Both receptors belong to the G-protein-coupled 
receptors type B (GPCR) family and are evolutionarily 
derived from the same ancestor gene through sequential 
phenomena of duplication and differentiation in paralogue 
structures coevolving together with their ligands (Irwin & 
Wong 2005, Hwang et al. 2014).
GLP-1 mainly acts through the classical GLP-1R 
(Cantini et  al. 2016); however, the expression of the 
receptor in the AT and in the adipose-derived precursor 
cells still remains debated (Vendrell et al. 2011, Muscogiuri 
et al. 2014, Cantini et al. 2015, 2017, El Bekay et al. 2016). 
GLP-1R expression has also been shown in human bone 
marrow-derived mesenchymal stem cells (Sanz et al. 2010, 
Lee et al. 2015). Here, we demonstrate by complementary 
techniques the expression of both GLP-1R and GCGR 
at protein level in human adipose precursors and in the 
corresponding AT.
Figure 6
GCGR and GLP-1R involvement underlying the anti-adipogenic effect of 
glucagon in human adipose precursor cells. ASCs were untreated (ASC) or 
in vitro induced to differentiate towards the adipose phenotype with the 
specific inductive media (ADIPO), with 10 nM glucagon (GLUC) or 
combined with an equimolar concentration (10 nM) of GCGR (GI) or 
GLP-1R (EX) antagonists. (A) Quantitative evaluation of intracellular 
triglyceride depots expressed as mean ± s.e. absorbance fold increase (FI) 
vs ADIPO after spectrofluorometric measurement of AdipoRed staining. 
Statistical analysis was performed with Student’s t test: P < 0.000 vs 
undifferentiated ASC, §P < 0.001 vs ADIPO, *P < 0.05, **P < 0.001 vs 
Gluc10, n = 7 independent experiments. (B) qRT-PCR TaqMan evaluation 
of adipose marker gene expression in in-vitro-differentiated adipocytes 
alone (ADIPO), treated with 10 nM glucagon (GLUC) or combined with an 
equimolar concentration (10 nM) of GCGR (GI) or GLP-1R (EX) antagonists. 
Bar-graph represents mean ± s.e. gene expression fold increase (FI) vs 
ADIPO. Statistical analysis was performed with Student’s t test: P < 0.000 
vs undifferentiated ASC, §P < 0.001 vs ADIPO, *P < 0.05, **P < 0.001 vs 
GLUC, n = 6 independent experiments. (C) qRT-PCR TaqMan evaluation of 
the adipose marker gene expression (FABP4) in in-vitro-differentiated 
adipocytes treated with 10 nM glucagon (GLUC) stimulated with an 
equimolar concentration (10 nM) of GCGR (GI) or GLP-1R (EX) antagonists 
alone or combined. Statistical analysis was performed with Student’s t 
test: P < 0.000 vs undifferentiated ASC and P < 0.001 vs ADIPO (not 
shown), *P < 0.05, **P < 0.001 vs GLUC, #P < 0.05 vs GI + EX combined, 
n = 4 independent experiments from two ASC populations.
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To make this scenario even more complex, the ability 
of glucagon to bind to and activate GLP-1R has been 
recently demonstrated in pancreatic beta-cells; in these 
cells, in conditions of high glucose, glucagon can stimulate 
insulin secretion through a specific binding to beta-cell 
GLP-1R (Svendsen et al. 2018). As mentioned earlier, such 
a ‘promiscuity’ of different GPCRs is further supported 
by evolutionary studies. It has been reported that some 
fishes (e.g., zebrafish) do not express a GLP-1R; instead, 
they have a related receptor, zfGPCR, with dual ligand 
selectivity for glucagon and GLP-1. The particular affinity 
of this receptor for the two ligands is due to the absence 
of the loop 3 in N-terminal extracellular domain of the 
receptor (NECD), which is responsible for ligand selectivity 
(Oren et al. 2016). Since we demonstrated the coexistence 
of both GCGR and GLP-1R in ASCs, we were interested in 
clarifying which receptor mediated the glucagon effects 
observed in the present study. To this purpose, we used 
the best available orthosteric antagonists for GCGR, des-
His1-[Glu9]-glucagon (Unson et  al. 1987) and exendin 
9-39 for GLP-1R (Thorensen et al. 1993), whose selectivity 
and specificity have been demonstrated in other systems 
(Unson et  al. 1991, Post et  al. 1993, Chepurny et  al. 
2019). The inhibitory effect exerted by glucagon on ASC 
proliferation was completely reverted by des-His1-[Glu9]-
glucagon (GI) and, to a lesser extent, by exendin 9-39. 
Similarly, the inhibitory effect GLP1 induced on ASC 
proliferation was reversible in the presence of GI. Since 
each antagonist has been demonstrated to be selective 
and specific for its respective receptor (Chepurny et  al. 
2019), with no cross-activity, these findings suggest that 
both receptors are necessary for mediating both glucagon 
and GLP-1 in ASCs, independently of the ligand. This 
conclusion is further supported by the absence of any 
synergistic effects in the block of proliferation obtained 
when glucagon and native GLP-1 were simultaneously 
administered to ASCs. Both receptor antagonists (GI and 
EX) were also able to revert the inhibitory effect exerted by 
glucagon on in vitro-induced adipogenesis (assessed by the 
intracellular lipid droplet quantification and the expression 
of mature adipocyte markers such as HSL and FABP4), 
when added during the differentiation. These findings 
support the existence of some promiscuity between 
GLP-1R and GCGR. The ability of both the antagonists 
of each receptor (GI and EX) to prevent glucagon 
inhibitory activity strongly suggests that glucagon can 
bind and activate both GCGR and GLP-1R (similarly 
to what happens in zebrafish and early in the receptor 
family evolution), and that both receptors are needed for 
mediating the glucagon activity. The concurrent block of 
both GLP-1R and GCGR by their respective antagonists 
reversed the inhibitory effect of glucagon on adipogenesis 
to a significantly higher extent than the inhibition of the 
single receptor blockade, suggesting that both receptors 
contribute to glucagon activity in ASCs. Similarly, both 
receptors are engaged in response to GLP-1. Interestingly, 
according to our results, ASCs seemed to express higher 
levels of GLP-1R compared to GCGR. Alternative 
mechanism of action of GLP-1 through non-canonical 
GLP-1R have been proposed to justify the effect of the 
truncated GLP-1 (9-36) form, which has a very low affinity 
for the classical receptor (Cantini et al. 2017), including the 
possibility of heterodimerization with GCGR on the cell 
surface (Cantini et al. 2016). Further studies are needed to 
elucidate the nature of the interaction of the two receptors 
and their reciprocal contribution in mediating the effects 
of glucagon and GLP-1.
Since the doses of glucagon used in this preclinical, 
in vitro study, were supraphysiological, the effects observed 
are not likely to occur in physiological conditions, or even 
at the increased levels of glucagon typical of obesity and 
diabetes. However, glucagon concentrations used in our 
experiments are consistent with the in vitro pharmacological 
studies.
We still need to improve our knowledge of the 
mechanisms underlying glucagon and GLP-1 effects on 
ASCs derived from different adipose depots. In fact, a 
different activity and susceptibility to metabolic alterations 
have been described in ASCs from subcutaneous (SAT) 
and visceral adipose tissue (VAT) (Baglioni et  al. 2012). 
However, the different susceptibility to glucagon and 
GLP-1 action between different fat depots in obese subjects 
is not within the aims of this study. Further, specifically 
designed studies are required for elucidating this aspect.
In conclusion, we demonstrate here for the first time 
that glucagon can directly act on human ASC interfering 
with their proliferation and differentiation, in a similar way 
as other ‘proglucagon-derived peptides’, such as liraglutide 
and GLP-1, through a still to be clarified mechanism of 
action. Glucagon activity requires the engagement of both 
GCGR and GLP-1R present on ASC surface. This novel 
glucagon action, here demonstrated in vitro in adipose 
cells, might contribute to the greater anti-adipose effect of 
glucagon/GLP-1 agonist combination, or of GLP-1/glucagon 
dual agonists, in comparison with specific GLP-1 agonists.
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